軟部肉腫(STS)の市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast-2028
◆商品コード:DATA00109004
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:180
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥712,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,137,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Soft Tissue Sarcoma (STS) Market Insights, Epidemiology, and Market Forecast-2028
DelveInsight’s ‘Soft Tissue Sarcoma (STS) – Market Insights, Epidemiology, and Market Forecast-2028’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of STS in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.

According to DelveInsight’s, STS have various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2028

Soft Tissue Sarcoma (STS) – Disease Understanding and Treatment Algorithm

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course.

Soft Tissue Sarcoma (STS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma (STS) in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.

According to DelveInsight’s, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2028).

Among all the seven major markets, United States accounts for highest number of cases of STS. In 2017, there were 12,390 incident cases of STS—which did not included GIST cases—in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

Soft Tissue Sarcoma (STS) Drug Chapters

STS are a heterogeneous group of malignancies and relatively rare that are characterized by mesodermal differentiation. It is primarily encountered in adults but can affect patients of any age. There are many histologic subtypes, and the malignancy can be low or high grade. Soft tissue sarcoma treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.

The emerging therapies are classified into four categories based on their line of therapy. The upcoming first-line therapies that are going to be launched in the forecasted period includes, AL3818 (anlotinib), Fibromun. The second-line emerging therapies includes, Vigil in combination with irinotecan and temozolomide, AL3818, GSK 3377794, Ripretinib (DCC-2618), Tazemetostat, Abemaciclib, Pembrolizumab, Crizotinib, ABI-009, and SRA737. The third-line emerging therapies includes, Avapritinib, Cabozantinib, and Selinexor. The fourth-line emerging therapies includes Avapritinib, TAS-116, Crenolanib, and Ripretinib.

Soft Tissue Sarcoma (STS) Market Outlook

According to DelveInsight, the total market size of Soft Tissue Sarcoma (STS) excluding GIST in seven major markets was USD 246.7 million in 2017. The market size of STS is expected to increase at a significant CAGR during the study period (2017–2028).

Among all the seven major markets, United States accounts for highest market size of STS. In 2017, the market size of STS (excluding GIST) was found to be USD 142.18 million.

Soft Tissue Sarcoma (STS) Drugs Uptake

The current market size of STS is mainly attributed by Votrient, Yondelis, Halaven and various anthracycline and non-anthracycline regimens. The market size of GIST in the United States was found to be USD 119.7 million in 2017 and expected to increase during the forecast period (2019-2028), due to potential therapies Vitrakvi, Rozlytrek, Avapritinib, Ripretinib and others. Among EU5, Germany had the highest market size in 2017 with revenue USD 22.06 million followed by Italy with revenue USD 18.84 million. The market size of STS (excluding GIST) in Japan was found to be USD 17.60 million in 2017.

Soft Tissue Sarcoma (STS) Report Insights

• Patient Population by total incident cases
• Type-specific incident cases of STS
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Soft Tissue Sarcoma (STS) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Soft Tissue Sarcoma (STS) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Soft Tissue Sarcoma (STS) market
• Organize sales and marketing efforts by identifying the best opportunities for Soft Tissue Sarcoma (STS) market
• To understand the future market competition in the Soft Tissue Sarcoma (STS) market.

【レポートの目次】

1. Key Insights
2. Soft-Tissue Sarcomas (STS) Market Overview at a Glance
2.1. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2017
2.2. Market Share (%) Distribution of Soft-Tissue Sarcomas (STS) in 2028
3. Soft-Tissue Sarcomas (STS): Disease Background and Overview
3.1. Introduction
3.2. Types of Soft-Tissue Sarcomas (STS)
3.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
3.4. Stages of Soft-Tissue Sarcomas (STS)
3.5. Diagnosis of Soft-Tissue Sarcomas (STS)
3.5.1. Medical History and Physical Exam
3.5.2. Imaging Tests
3.5.3. Biopsy
3.5.4. Pathological diagnosis of soft tissue sarcomas
3.5.5. Proposed Diagnostic Guidelines
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)
5. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)
5.1. United States Epidemiology
5.1.1. Assumptions and Rationale
5.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
5.1.3. Type-Specific Incidence of STS in the United States
5.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
5.1.5. Total Incident Cases of STS including GIST in the United States
5.1.6. Incidence of STS by Extremities (%) in the United States
5.2. EU5 Epidemiology
5.2.1. Germany
5.2.1.1. Assumptions and Rationale
5.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
5.2.1.3. Gender-Specific Incidence of STS in Germany
5.2.1.4. Type-Specific Incidence of STS in Germany
5.2.1.5. Age-Specific Incidence of STS in Germany
5.2.1.6. Stage-Specific Incidence of STS in Germany
5.2.1.7. Incidence of STS by Extremities (%) in Germany
5.2.2. France
5.2.2.1. Assumptions and Rationale
5.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
5.2.2.3. Gender-Specific Incidence of STS in France
5.2.2.4. Type-Specific Incidence of STS in France
5.2.2.5. Age-Specific Incidence of STS in France
5.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
5.2.2.7. Incidence of STS by Extremities (%) in France
5.2.3. Italy
5.2.3.1. Assumptions and Rationale
5.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
5.2.3.3. Gender-Specific Incidence of STS in Italy
5.2.3.4. Type-Specific Incidence of STS in Italy
5.2.3.5. Age-Specific Incidence of STS in Italy
5.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
5.2.3.7. Incident of STS by Extremities (%) in Italy
5.2.4. Spain
5.2.4.1. Assumptions and Rationale
5.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
5.2.4.3. Gender-Specific Incidence of STS in Spain
5.2.4.4. Type-Specific Incidence of STS in Spain
5.2.4.5. Age-Specific Incidence of STS in Spain
5.2.4.6. Stage-Specific Incidence of STS in Spain
5.2.4.7. Incident of STS by Extremities (%) in Spain
5.2.5. United Kingdom
5.2.5.1. Assumptions and Rationale
5.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
5.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
5.2.5.4. Type-Specific Incidence of STS in the United Kingdom
5.2.5.5. Age-Specific Incidence of STS in the United Kingdom
5.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
5.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
5.3. Japan Epidemiology
5.3.1. Assumptions and Rationale
5.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
5.3.3. Gender-Specific Incidence of STS in Japan
5.3.4. Type-Specific Incidence of STS in Japan
5.3.5. Age-Specific Incidence of STS in Japan
5.3.6. Stage-Specific Incidence of STS in Japan
5.3.7. Incident of STS by Extremities (%) in Japan
6. Treatment and Management of Soft Tissue Sarcoma (STS)
6.1. Stage-wise Treatment
6.2. Treatment Algorithms
6.3. Treatment Guidelines
6.3.1. UK guidelines for the management of soft tissue sarcomas
6.3.2. NCCN guidelines for the management of soft tissue sarcomas
6.3.3. Soft Tissue and Visceral Sarcomas: ESMO-EURACAN Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up
7. Unmet Needs
8. Marketed Drugs
8.1. Halaven (Eribulin Mesylate): Eisai
8.1.1. Product Description
8.1.2. Regulatory Milestones
8.1.3. Clinical Development
8.1.4. Ongoing Current Pipeline Activity
8.1.5. Safety and efficacy
8.1.6. Product Profile
8.2. Gleevec (Imatinib Mesylate): Novartis
8.2.1. Product Description
8.2.2. Regulatory Milestones
8.2.3. Clinical Development
8.2.4. Safety and efficacy
8.2.5. Product Profile
8.3. Yondelis (Trabectedin): Pharma Mar
8.3.1. Product Description
8.3.2. Regulatory Milestones
8.3.3. Clinical Development
8.3.4. Safety and efficacy
8.3.5. Product Profile
8.4. Lartruvo (Olaratumab): Eli Lilly
8.4.1. Product Description
8.4.2. Regulatory Milestones
8.4.3. Clinical Development
8.4.4. Safety and efficacy
8.4.5. Product Profile
8.5. Vitrakvi (Larotrectinib; BAY2757556): Bayer/Loxo Oncology
8.5.1. Product Description
8.5.2. Regulatory Milestones
8.5.3. Clinical Development
8.5.4. Safety and efficacy
8.5.5. Product Profile
8.6. Stivarga (Regorafenib): Bayer
8.6.1. Product Description
8.6.2. Regulatory Milestones
8.6.3. Clinical Development
8.6.4. Ongoing Current Pipeline Activity
8.6.5. Safety and efficacy
8.6.6. Product Profile
8.7. Sutent (Sunitinib malate): Pfizer
8.7.1. Product Description
8.7.2. Regulatory Milestones
8.7.3. Clinical Development
8.7.4. Safety and efficacy
8.7.5. Product Profile
8.8. Votrient (Pazopanib): GlaxoSmithKline/Novartis
8.8.1. Product Description
8.8.2. Regulatory Milestones
8.8.3. Clinical Development
8.8.4. Ongoing Current Pipeline Activity
8.8.5. Safety and efficacy
8.8.6. Product Profile
8.9. Vincristine Sulfate: Hospira
8.9.1. Product Description
8.9.2. Regulatory Milestones
8.9.3. Product Profile
8.10. Rozlytrek (Entrectinib): Roche (Genentech)
8.10.1. Product Description
8.10.2. Regulatory Milestones
8.10.3. Safety and Efficacy of Rozlytrek
8.10.4. Clinical trial information
8.10.5. Product Profile
9. Emerging Drugs
9.1. Key Cross Competition
10. Phase III Emerging Molecules
10.1. Avapritinib (BLU-285): Blueprint Medicines Corporation
10.1.1. Product Description
10.1.2. Other Development Activities
10.1.3. Clinical Development
10.1.4. Clinical Trials Information
10.1.5. Safety and Efficacy
10.1.6. Product Profile
10.2. Vigil (In combination with irinotecan and temozolomide): Gradalis
10.2.1. Product Description
10.2.2. Other Development Activities
10.2.3. Clinical Development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Anlotinib (AL3818): Advenchen Laboratories/Jiangsu Chia-Tai Tianqing Pharmaceutical
10.3.1. Product Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Safety and Efficacy
10.3.6. Product Profile
10.4. Selinexor: Karyopharm Therapeutics
10.4.1. Product Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5. Aldoxorubicin (INNO-206): CytRx
10.5.1. Product Description
10.5.2. Other Development Activities
10.5.3. Clinical Development
10.5.4. Clinical Trials Information
10.5.5. Safety and Efficacy
10.5.6. Product Profile
10.6. Ripretinib (DCC-2618): Deciphera Pharmaceuticals
10.6.1. Product Description
10.6.2. Other Development Activities
10.6.3. Clinical Development
10.6.4. Clinical Trials Information
10.6.5. Safety and Efficacy
10.6.6. Product Profile
10.7. Fibromun (In combination with Doxorubicin): Philogen
10.7.1. Product Description
10.7.2. Other Development Activities
10.7.3. Clinical Development
10.7.4. Clinical Trials Information
10.7.5. Product Profile
10.8. Hensify (NBTXR3): Nanobiotix
10.8.1. Product Description
10.8.2. Other Development Activities
10.8.3. Clinical Development
10.8.4. Clinical Trials Information
10.8.5. Safety and efficacy
10.8.6. Product Profile
10.9. Crenolanib: Arog Pharmaceuticals
10.9.1. Product Description
10.9.2. Other Development Activities
10.9.3. Clinical Development
10.9.4. Clinical Trials Information
10.9.5. Safety and Efficacy
10.9.6. Product Profile
10.10. TAS-116: Taiho Pharmaceutical
10.10.1. Product Description
10.10.2. Clinical Development
10.10.3. Clinical Trials Information
10.10.4. Safety and Efficacy
10.10.5. Product Profile
11. Phase II Emerging Molecules
11.1. GSK3377794: GlaxoSmithKline/ Adaptimmune
11.1.1. Product Description
11.1.2. Other Development Activities
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and Efficacy
11.1.6. Product Profile
11.2. ADP-A2M4: Adaptimmune
11.2.1. Product Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and Efficacy
11.2.6. Product Profile
11.3. Tazemetostat (EPZ-6438): Epizyme
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Clinical Trials Information
11.3.5. Safety and Efficacy
11.3.6. Product Profile
11.4. AMG 337: NantPharma/ Amgen
11.4.1. Product Description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Clinical Trials Information
11.4.5. Safety and Efficacy
11.4.6. Product Profile
11.5. GB226/APL-501: Genor Biopharma /Apollomics (Previously CBT Pharmaceuticals)
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Clinical Trials Information
11.5.5. Product Profile
11.6. Camsirubicin: Monopar Therapeutics /Gem Pharmaceuticals
1.1.1. Product Description
1.1.2. Other Development Activities
1.1.3. Clinical Development
1.1.4. Clinical Trials Information
1.1.5. Safety and Efficacy
1.1.6. Product Profile
1.2. LTX-315: Lytix Biopharma
1.2.1. Product Description
1.2.2. Other Development Activities
1.2.3. Clinical Development
1.2.4. Clinical Trials Information
1.2.5. Safety and Efficacy
1.2.6. Product Profile
1.3. Abemaciclib (LY2835219): Eli Lilly and Company
1.3.1. Product Description
1.3.2. Other Development Activities
1.3.3. Clinical Development
1.3.4. Clinical Trials Information
1.3.5. Safety and Efficacy
1.3.6. Product Profile
1.4. Pembrolizumab: Merck Sharp & Dohme Corp.
1.4.1. Product Description
1.4.2. Other Development Activities
1.4.3. Clinical Development
1.4.4. Clinical Trials Information
1.4.5. Safety and Efficacy
1.4.6. Product Profile
1.5. Crizotinib (PF-02341066): Pfizer
1.5.1. Product Description
1.5.2. Other Development Activities
1.5.3. Clinical Development
1.5.4. Clinical Trials Information
1.5.5. Safety and Efficacy
1.5.6. Product Profile
1.6. ABI-009: Aadi Bioscience
1.6.1. Product Description
1.6.2. Other Development Activities
1.6.3. Clinical Development
1.6.4. Clinical Trials Information
1.6.5. Safety and Efficacy
1.6.6. Product Profile
1.7. Nivolumab: Bristol-Myers Squibb
1.7.1. Product Description
1.7.2. Other Development Activities
1.7.3. Clinical Development
1.7.4. Clinical Trials Information
1.7.5. Safety and Efficacy
1.7.6. Product Profile
1.8. Sorafenib Tosylate: Bayer
1.8.1. Product Description
1.8.2. Clinical Development
1.8.3. Clinical Trials Information
1.8.4. Safety and Efficacy
1.8.5. Product Profile
1.9. Doxorubicin with AGEN1884 and AGEN2034: Agenus
1.9.1. Product Description
1.9.2. Clinical Development
1.9.3. Clinical Trials Information
1.9.4. Product Profile
1.10. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine
1.10.1. Product Description
1.10.2. Clinical Development
1.10.3. Clinical Trials Information
1.10.4. Product Profile
1.11. Atezolizumab: Roche Pharma AG
1.11.1. Product Description
1.11.2. Clinical Development
1.11.3. Clinical Trials Information
1.11.4. Product Profile
1.12. Spartalizumab (PDR001): Novartis Pharmaceuticals
1.12.1. Product Description
1.12.2. Other Development Activities
1.12.3. Clinical Development
1.12.4. Clinical Trials Information
1.12.5. Product Profile
1.13. Iclusig (Ponatinib): Takeda
1.13.1. Product Description
1.13.2. Other Development Activities
1.13.3. Clinical Development
1.13.4. Clinical Trials Information
1.13.5. Safety and Efficacy
1.13.6. Product Profile
1.14. Temozolomide (Temodar): Merck
1.14.1. Product Description
1.14.2. Other Developmental Activities:
1.14.3. Clinical Development
1.14.4. Clinical trial information
1.14.5. Product Profile
1.15. Cabozantinib: Exelixis
1.15.1. Product Description
1.15.2. Other Developmental Activities:
1.15.3. Clinical Development
1.15.4. Clinical trial information
1.15.5. Safety and Efficacy
1.15.6. Product Profile
1.16. Avelumab: Merck KGaA
1.16.1. Product Description
1.16.2. Other Developmental Activities:
1.16.3. Clinical Development
1.16.4. Clinical trial information
1.16.5. Product Profile
2. Phase I/II Emerging Molecules
2.1. Lenvatinib (In Combination with Everolimus): Eisai
2.1.1. Product Description
2.1.2. Other Development Activities
2.1.3. Clinical Development
2.1.4. Clinical Trials Information
2.1.5. Product Profile
2.2. SRA737: Sierra Oncology
2.2.1. Product Description
2.2.2. Other Development Activities
2.2.3. Clinical Development
2.2.4. Clinical Trials Information
2.2.5. Safety and Efficacy
2.2.6. Product Profile
2.3. Nab-paclitaxel: Celgene
2.3.1. Product Description
2.3.2. Other Developmental Activities
2.3.3. Clinical Development
2.3.4. Clinical Trials Information
2.3.5. Safety and Efficacy
2.3.6. Product Profile
2.4. Afatinib: Boehringer Ingelheim
2.4.1. Product Description
2.4.2. Other Development Activities
2.4.3. Clinical Development
2.4.4. Clinical Trials Information
2.4.5. Safety and Efficacy
2.4.6. Product Profile
2.5. IMCnyeso (GSK01): GlaxoSmithKline/Immunocore
2.5.1. Product Description
2.5.2. Other Development Activities
2.5.3. Clinical Development
2.5.4. Clinical Trials Information
2.5.5. Product Profile
2.6. CAR-T/TCR-T Cell Immunotherapy: Shenzhen BinDeBio
2.6.1. Product Description
2.6.2. Other Development Activities
2.6.3. Clinical Development
2.6.4. Clinical Trials Information
2.6.5. Product Profile
2.7. Epirubicin Micelle (NC-6300; K-912): NanoCarrier
2.7.1. Product Description
2.7.2. Other Development Activities
2.7.3. Clinical Development
2.7.4. Clinical Trials Information
2.7.5. Safety and Efficacy
2.7.6. Product Profile
2.8. Copanlisib (BAY806946): Bayer
2.8.1. Product Description
2.8.2. Other Developmental Activities
2.8.3. Clinical Development
2.8.4. Clinical Trials Information
2.8.5. Product Profile
2.9. PLX9486: Plexxikon
2.9.1. Product Description
2.9.2. Clinical Development
2.9.3. Clinical Trials Information
2.9.4. Safety and Efficacy
2.9.5. Product Profile
2.10. BA3021: BioAtla
2.10.1. Product Description
2.10.2. Other Developmental Activities
2.10.3. Clinical Development
2.10.4. Clinical Trials Information
2.10.5. Product Profile
2.11. Tinostamustine (EDO-S101): Mundipharma-EDO GmbH
2.11.1. Product Description
2.11.2. Other Developmental Activities
2.11.3. Clinical Development
2.11.4. Clinical Trials Information
2.11.5. Safety and Efficacy
2.11.6. Product Profile
2.12. TBI-1301 (NY-ESO-1 T cell Receptor Gene Transduced Autologous T Lymphocytes): Takara Bio.
2.12.1. Product Description
2.12.2. Other Developmental Activities
2.12.3. Clinical Development
2.12.4. Clinical Trials Information
2.12.5. Safety and Efficacy
2.12.6. Product Profile
2.13. Ramucirumab (LY3009806): Eli Lilly and Company
2.13.1. Product Description
2.13.2. Clinical Development
2.13.3. Clinical Trials Information
2.13.4. Product Profile
2.14. TB-403: Oncurious NV
2.14.1. Product Description
2.14.2. Other Developmental Activities
2.14.3. Clinical Development
2.14.4. Clinical Trials Information
2.14.5. Product Profile
2.15. TLC178: Taiwan Liposome Company
2.15.1. Product Description
2.15.2. Other Development Activities
2.15.3. Clinical Development
2.15.4. Clinical Trials Information
2.15.5. Safety and Efficacy
2.15.6. Product Profile
2.16. Talimogene Laherparepvec (T-VEC): Amgen
2.16.1. Product Description
2.16.2. Other Developmental Activities
2.16.3. Clinical Development
2.16.4. Clinical Trials Information
2.16.5. Safety and Efficacy
2.16.6. Product Profile
2.17. MEK162: Array BioPharma
2.17.1. Product Description
2.17.2. Clinical Development
2.17.3. Clinical Trials Information
2.17.4. Safety and Efficacy
2.17.5. Product Profile
2.18. Neoadjuvant Durvalumab and Tremelimumab: AstraZeneca
2.18.1. Product Description
2.18.2. Clinical Development
2.18.3. Clinical Trials Information
2.18.4. Safety and Efficacy
2.18.5. Product Profile
2.19. Selpercatinib (LOXO-292): Eli Lilly/Loxo Oncology
2.19.1. Product Description
2.19.2. Other Development Activities
2.19.3. Clinical Development
2.19.4. Clinical Trials Information
2.19.5. Product Profile
3. Soft Tissue Sarcoma (STS): 7 Major Market Analysis
3.1. Key Findings
3.2. Market Size of metastatic Soft Tissue Sarcoma (STS) in the 7MM
3.3. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the 7MM
4. Market Outlook: The United States
4.1. United States Market Size
4.1.1. Total market size of Soft Tissue Sarcoma (STS)*
4.1.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United States
5. Market Outlook: Europe
5.1. Germany
5.1.1. The total market size of Soft Tissue Sarcoma (STS)
5.1.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Germany
5.2. France
5.2.1. Total Market size of Soft Tissue Sarcoma (STS)
5.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in France
5.3. Italy
5.3.1. Total Market size of Soft Tissue Sarcoma (STS)
5.3.2. Market Size of Soft Tissue Sarcoma (STS) by Therapies in Italy
5.4. Spain
5.4.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
5.4.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Spain
5.5. United Kingdom
5.5.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
5.5.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in the United Kingdom (UK)
6. Market Outlook: Japan
6.1. Total Market size of metastatic Soft Tissue Sarcoma (STS)
6.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Therapies in Japan
6.2.1. Market Size of metastatic Soft Tissue Sarcoma (STS) by First-line of Therapies in Japan
6.2.2. Market Size of metastatic Soft Tissue Sarcoma (STS) by Second-Line & Later Line Therapies in Japan
7. Market Drivers
8. Market Barriers
9. Appendix
9.1. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Safety and Efficacy
11.6.6. Product Profile
11.7. LTX-315: Lytix Biopharma
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.4. Clinical Trials Information
11.7.5. Safety and Efficacy
11.7.6. Product Profile
11.8. Abemaciclib (LY2835219): Eli Lilly and Company
11.8.1. Product Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.4. Clinical Trials Information
11.8.5. Safety and Efficacy
11.8.6. Product Profile
11.9. Pembrolizumab: Merck Sharp & Dohme Corp.
11.9.1. Product Description
11.9.2. Other Development Activities
11.9.3. Clinical Development
11.9.4. Clinical Trials Information
11.9.5. Safety and Efficacy
11.9.6. Product Profile
11.10. Crizotinib (PF-02341066): Pfizer
11.10.1. Product Description
11.10.2. Other Development Activities
11.10.3. Clinical Development
11.10.4. Clinical Trials Information
11.10.5. Safety and Efficacy
11.10.6. Product Profile
11.11. ABI-009: Aadi Bioscience
11.11.1. Product Description
11.11.2. Other Development Activities
11.11.3. Clinical Development
11.11.4. Clinical Trials Information
11.11.5. Safety and Efficacy
11.11.6. Product Profile
11.12. Nivolumab: Bristol-Myers Squibb
11.12.1. Product Description
11.12.2. Other Development Activities
11.12.3. Clinical Development
11.12.4. Clinical Trials Information
11.12.5. Safety and Efficacy
11.12.6. Product Profile
11.13. Sorafenib Tosylate: Bayer
11.13.1. Product Description
11.13.2. Clinical Development
11.13.3. Clinical Trials Information
11.13.4. Safety and Efficacy
11.13.5. Product Profile
11.14. Doxorubicin with AGEN1884 and AGEN2034: Agenus
11.14.1. Product Description
11.14.2. Clinical Development
11.14.3. Clinical Trials Information
11.14.4. Product Profile
11.15. Apatinib Mesylate (In Combination with Doxorubicin and Ifosfamide: Jiangsu HengRui Medicine
11.15.1. Product Description
11.15.2. Clinical Development
11.15.3. Clinical Trials Information
11.15.4. Product Profile
11.16. Atezolizumab: Roche Pharma AG
11.16.1. Product Description
11.16.2. Clinical Development
11.16.3. Clinical Trials Information
11.16.4. Product Profile
11.17. Spartalizumab (PDR001): Novartis Pharmaceuticals
11.17.1. Product Description
11.17.2. Other Development Activities
11.17.3. Clinical Development
11.17.4. Clinical Trials Information
11.17.5. Product Profile
11.18. Iclusig (Ponatinib): Takeda
11.18.1. Product Description
11.18.2. Other Development Activities
11.18.3. Clinical Development
11.18.4. Clinical Trials Information
11.18.5. Safety and Efficacy
11.18.6. Product Profile
11.19. Temozolomide (Temodar): Merck
11.19.1. Product Description
11.19.2. Other Developmental Activities:
11.19.3. Clinical Development
11.19.4. Clinical trial information
11.19.5. Product Profile
11.20. Cabozantinib: Exelixis
11.20.1. Product Description
11.20.2. Other Developmental Activities:
11.20.3. Clinical Development
11.20.4. Clinical trial information
11.20.5. Safety and Efficacy
11.20.6. Product Profile
11.21. Avelumab: Merck KGaA
11.21.1. Product Description
11.21.2. Other Developmental Activities:
11.21.3. Clinical Development
11.21.4. Clinical trial information
11.21.5. Product Profile
Table 1 The IGF System in Sarcoma Pathogenesis
Table 2 Trunk and Extremities Sarcoma Stages
Table 3 Incident Patient Population of STS in the 7MM (2017–2028)
Table 4 Total Incident Population of STS in the United States (2017–2028)
Table 5 Type-Specific Incidence of STS in the US (2017-2028)
Table 6 Total Incident Population of GIST in the United States (2017–2028)
Table 7 Total Incident Population of STS including GIST in the United States (2017–2028)
Table 8 Gender-Specific Incidence of STS in the United States (2017–2028)
Table 9 Age-Specific Incidence of STS in the United States (2017-2028)
Table 10 Stage-Specific Incidence of STS in the United States (2017-2028)
Table 11 Incidence of STS* by Extremities (%) in the United States (2017–2028)
Table 12 Total Incident Population of STS in Germany (2017–2028)
Table 13 Gender-Specific Incidence of STS in Germany (2017–2028)
Table 14 Type-Specific Incidence of STS in Germany (2017-2028)
Table 15 Age-Specific Incidence of STS in Germany (2017-2028)
Table 16 Stage-Specific Incidence of STS in Germany (2017-2028)
Table 17 Incidence of STS by Extremities (%) in Germany (2017–2028)
Table 18 Total Incident Population of STS in France (2017–2028)
Table 19 Gender-Specific Incidence of STS in France (2017–2028)
Table 20 Type-Specific Incidence of STS in France (2017-2028)
Table 21 Age-Specific Incidence of STS in France (2017-2028)
Table 22 Stage-Specific Incidence of STS in France (2017-2028)
Table 23 Incidence of STS by Extremities (%) in France (2017–2028)
Table 24 Total Incident Population of STS in Italy (2017–2028)
Table 25 Gender-Specific Incidence of STS in Italy (2017–2028)
Table 26 Type-Specific Incidence of STS in Italy (2017-2028)
Table 27 Age-Specific Incidence of STS in Italy (2017-2028)
Table 28 Stage-Specific Incidence of STS in Italy (2017-2028)
Table 29 Incident of STS by Extremities (%) in Italy (2017–2028)
Table 30 Total Incident Population of STS in Spain (2017–2028)
Table 31 Gender-Specific Incidence of STS in Spain (2017–2028)
Table 32 Type-Specific Incidence of STS in Spain (2017-2028)
Table 33 Age-Specific Incidence of STS in Spain (2017-2028)
Table 34 Stage-Specific Incidence of STS in Spain (2017-2028)
Table 35 Incident of STS by Extremities (%) in Spain (2017–2028)
Table 36 Total Incident Population of STS in the United Kingdom (2017–2028)
Table 37 Gender-Specific Incidence of STS in the United Kingdom (2017–2028)
Table 38 Type-Specific Incidence of STS in the UK (2017-2028)
Table 39 Age-Specific Incidence of STS in the United Kingdom (2017-2028)
Table 40 Stage-Specific Incidence of STS in the United Kingdom (2017-2028)
Table 41 Incident of STS by Extremities (%) in the United Kingdom (2017–2028)
Table 42 Total Incident Population of STS in Japan (2017–2028)
Table 43 Gender-Specific Incidence of STS in Japan (2017–2028)
Table 44 Type-Specific Incidence of STS in Japan (2017-2028)
Table 45 Age-Specific Incidence of STS in Japan (2017-2028)
Table 46 Stage-Specific Incidence of STS in Japan (2017-2028)
Table 47 Incident of STS by Extremities (%) in Japan (2017–2028)
Table 48 Novel and Targeted Agents for the Treatment of Soft-Tissue Sarcomas
Table 49 Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System)
Table 50 Recommended dressings for neonates with EB



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[軟部肉腫(STS)の市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆